Quantitative relationship between pharmacokinetics of unchange cisplatin and nephrotoxicity in rats: Importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 1, 1997, Pages 11-18

  Nagai, Naomi ^a   Ogata, Hiroyasu ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Area under the concentration time curve (AUC); Nephrotoxicity; Pharmacokinetic pharmacodynamic relationship; Unchanged cisplatin

Indexed keywords

CISPLATIN; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MALE; MATHEMATICAL MODEL; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; KIDNEY; MALE; RATS; RATS, WISTAR;

EID: 0030889525     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050618     Document Type: Article

References (36)

1. Ali-Osman F, Giblin J, Dougherty D, Rosenblum ML (1987) Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. Cancer Res 47:3718
2. Andersson A, Ehrsson H (1994) Determination of cisplatin and cis-diammineaquachloroplatinum (II) ion by liquid chromatography using post-column derivatization with diethyldithiocarbamate. J Chromatogr 652:203
3. Andersson A, Hedenmalm H, Elfsson B, Ehrsson H (1994) Determination of the acid dissociation constant for cis-diammineaquachloroplatinum (II) ion, a hydrolysis product of cisplatin. J Pharm Sci 83:859
4. Belliveau JF, Posner MR, Ferrari L, Crabtree GW, Cummings FJ, Wiemann MC, O'Leary GP, Griffin H, Phaneuf MA, O'Rourke A, Calabresi P (1986) Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion. Cancer Treat Rep 70:1215
5. Bozzino JM, Prasad V, Koriech OM (1981) Avoidance of renal toxicity by 24-hour infusion of cisplatin. Cancer Treat Rep 65:351
6. Daley-Yates PT, McBrien DCH (1982) The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum II) and its modification by furosemide and probenecid. Biochem Pharmacol 31:2243
7. Davidson WD, Sackner MA (1963) Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 62:351
8. Drewinko B, Brown BW, Gottlieb JA (1973) Effect of cisdiamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 33:3091
9. Fillastre JP, Raguenez-Viotte G (1989) Cisplatin nephrotoxicity. Toxicol Lett 46:163
10. Forastiere AA, Belliveau JF, Goren MP, Vogel WC, Posner MR, O'Leary GP (1988) Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diammine dichloroplatinum (II) in head and neck cancer patients. Cancer Res 48:3869
11. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180
12. Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D (eds) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, p 409
13. Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF, Woolley PV (1980) Pharmacokinetics and protein binding of eisdichlorodiammineplatinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol 5:21
14. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cis-platinumdiamminedichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372
15. Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43:1426
16. Kinoshita M, Yoshimura N, Ogata H, Tsujino D, Takahashi T, Takahashi S, Wada Y, Ohno Y, Masuhara K, Tanaka Y (1990) High-performance liquid chromatographic analysis of unchanged cis-diamminedichloroplatinum (cisplatin) in plasma and urine with post-column derivatization J Chromatogr 529:462
17. Ma J, Verweij J, Kolker HJ, van Ingen HE, Stoter G, Schellens JHM (1994) Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion. Br J Cancer 69:858
18. Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65:307
19. Nagai N, Hotta K, Yamamura H, Ogata H (1995) Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity. Cancer Chemother Pharmacol 36:404
20. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus 24-hour infusion. Clin Cancer Res 1:599
21. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M (1988) Cell killing action of cell cycle phase-nonspecific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol 21:185
22. Ozawa S, Sugiyama Y, Mitsuhashi J, Inaba M (1989) Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res 49:3823
23. Patton TF, Repta AJ, Sternson LA, Belt RJ (1982) Pharmacokinetics of intact cisplatin in plasma. Infusion versus bolus dosing. Int J Pharm 10:77
24. Powis G (1985) Anticancer drug pharmacodynamics. Cancer Chemother pharmacol 14:177
25. Reece PA, Stafford I, Davy M, Morris R, Freeman S (1989) Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. Cancer Chemother Pharmacol 24:256
26. Safirstein R, Miller P, Guttenplan JB (1984) Uptake and metabolism of cisplatin by rat kidney. Kidney Int 25:753
27. Sakuma A (1977) Analysis of variance; nonparametric procedure. In: Sakuma A (ed) Statistical methods in pharmacometrics I, II (in Japanese). University of Tokyo Press, Tokyo, I p 220; II P 1
28. Sakuma A (1977) Analysis of variance; nonparametric procedure. In: Sakuma A (ed) Statistical methods in pharmacometrics I, II (in Japanese). University of Tokyo Press, Tokyo, I p 220; II P 1
29. Salem P, Khalyl M, Jabboury K, Hashimi L (1984) Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer 53:837
30. Skipper HE, Schabel FM, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW (1970) Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54:431
31. Sugiyama Y, Hanano M, Sawada Y (1987) Program NLS. In: Hanano M (ed) Pharmacokinetics (in Japanese). Nanzando Press, Tokyo, p 113
32. Sugiyama Y, Kobayashi T, Inaba M (1987) Quantitative analysis of cell-kill effects of anticancer drugs: consideration of both in vitro and in vivo experimental systems, (abstract in English) Jpn J Cancer Chemother 14:3183
33. Takahashi A, Takagi M, Hishida H, Saji E, Takagi N, Amano H, Ogura Y (1987) The pharmacokinetics of cisplatin and its influence on renal function according to different infusion methods. (abstract in English) Jpn J Cancer Chemother 14:2944
34. Vermorken JB, van der Vijgh WJF, Klein I, Gall HE, Pinedo HM (1982) Pharmacokinetics of free platinum species following rapid. 3-hour and 24-hour infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. Eur J Cancer Clin Oncol 18:1069
35. Vermorken JB, van der Vijgh WJF, Klein I, Gall HE, van Groeningen CJ, Hart GAM, Pinedo HM (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39:136
36. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equation. J pharmacokinet Biopharm 6:165